FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898093807> ?p ?o ?g. }

• W2898093807 endingPage "101042831880867" @default.
• W2898093807 startingPage "101042831880867" @default.
• W2898093807 abstract "Chemotherapy-induced neuropathy is a highly problematic, dose-limiting effect of potentially curative regimens of cancer chemotherapy. When neuropathic pain is severe, patients often either switch to less-effective chemotherapy agents or choose to discontinue chemotherapy entirely. Conventional chemotherapy drugs used to treat lung and breast cancer, multiple myeloma, and lymphoma include paclitaxel, vincristine, and bortezomib. Approximately 68% of patients receiving these anticancer drugs develop neuropathy within the first month of treatment, and while strategies to prevent chemotherapy-induced neuropathy have been investigated, none have yet been proven as effective. Recent reports suggest that chemotherapy-induced neuropathy is associated with signal transduction molecules, including protein kinase C and mitogen-activated protein kinases. It is currently unclear whether protein kinase C inhibition can prevent chemotherapy-induced neuropathy. In this study, we found that tamoxifen, a protein kinase C inhibitor, suppressed paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice. In addition, chemotherapy drugs induce neuropathy via the protein kinase C/extracellular signal-regulated kinase pathway in the spinal cord in lumbar segments 4-6 and dorsal root ganglions. In addition, tamoxifen was shown to act synergistically with paclitaxel to inhibit tumor-growth in mice injected with tumor cells. Our results indicated that paclitaxel-, vincristine-, and bortezomib-induced neuropathies were associated with the protein kinase C/extracellular signal-regulated kinase pathway in the lumbar spinal cord and dorsal root ganglions, which suggest that protein kinase C inhibitors may be therapeutically effective for the prevention of chemotherapy-induced neuropathy when administered with standard chemotherapy agents." @default.
• W2898093807 created "2018-11-02" @default.
• W2898093807 creator A5011158695 @default.
• W2898093807 creator A5011985114 @default.
• W2898093807 creator A5039005762 @default.
• W2898093807 creator A5042160668 @default.
• W2898093807 creator A5045173622 @default.
• W2898093807 creator A5073470102 @default.
• W2898093807 creator A5073960923 @default.
• W2898093807 creator A5085469013 @default.
• W2898093807 creator A5089022781 @default.
• W2898093807 date "2018-10-25" @default.
• W2898093807 modified "2023-10-18" @default.
• W2898093807 title "Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathway" @default.
• W2898093807 cites W1544180852 @default.
• W2898093807 cites W1920937245 @default.
• W2898093807 cites W1973121417 @default.
• W2898093807 cites W1991888111 @default.
• W2898093807 cites W2036139631 @default.
• W2898093807 cites W2039650615 @default.
• W2898093807 cites W2047384875 @default.
• W2898093807 cites W2059190124 @default.
• W2898093807 cites W2068849989 @default.
• W2898093807 cites W2085665378 @default.
• W2898093807 cites W2096370405 @default.
• W2898093807 cites W2096812066 @default.
• W2898093807 cites W2100485228 @default.
• W2898093807 cites W2109879418 @default.
• W2898093807 cites W2111443510 @default.
• W2898093807 cites W2112772593 @default.
• W2898093807 cites W2113758041 @default.
• W2898093807 cites W2114826333 @default.
• W2898093807 cites W2129155568 @default.
• W2898093807 cites W2142408851 @default.
• W2898093807 cites W2148761780 @default.
• W2898093807 cites W2200143976 @default.
• W2898093807 cites W2516277153 @default.
• W2898093807 cites W2728026804 @default.
• W2898093807 cites W293260129 @default.
• W2898093807 doi "https://doi.org/10.1177/1010428318808670" @default.
• W2898093807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30360692" @default.
• W2898093807 hasPublicationYear "2018" @default.
• W2898093807 type Work @default.
• W2898093807 sameAs 2898093807 @default.
• W2898093807 citedByCount "19" @default.
• W2898093807 countsByYear W28980938072019 @default.
• W2898093807 countsByYear W28980938072020 @default.
• W2898093807 countsByYear W28980938072021 @default.
• W2898093807 countsByYear W28980938072022 @default.
• W2898093807 countsByYear W28980938072023 @default.
• W2898093807 crossrefType "journal-article" @default.
• W2898093807 hasAuthorship W2898093807A5011158695 @default.
• W2898093807 hasAuthorship W2898093807A5011985114 @default.
• W2898093807 hasAuthorship W2898093807A5039005762 @default.
• W2898093807 hasAuthorship W2898093807A5042160668 @default.
• W2898093807 hasAuthorship W2898093807A5045173622 @default.
• W2898093807 hasAuthorship W2898093807A5073470102 @default.
• W2898093807 hasAuthorship W2898093807A5073960923 @default.
• W2898093807 hasAuthorship W2898093807A5085469013 @default.
• W2898093807 hasAuthorship W2898093807A5089022781 @default.
• W2898093807 hasBestOaLocation W28980938071 @default.
• W2898093807 hasConcept C126322002 @default.
• W2898093807 hasConcept C134018914 @default.
• W2898093807 hasConcept C2776364478 @default.
• W2898093807 hasConcept C2776694085 @default.
• W2898093807 hasConcept C2776755627 @default.
• W2898093807 hasConcept C2777292972 @default.
• W2898093807 hasConcept C2777478702 @default.
• W2898093807 hasConcept C2779289229 @default.
• W2898093807 hasConcept C2779429289 @default.
• W2898093807 hasConcept C2779901536 @default.
• W2898093807 hasConcept C502942594 @default.
• W2898093807 hasConcept C555293320 @default.
• W2898093807 hasConcept C71924100 @default.
• W2898093807 hasConcept C98274493 @default.
• W2898093807 hasConceptScore W2898093807C126322002 @default.
• W2898093807 hasConceptScore W2898093807C134018914 @default.
• W2898093807 hasConceptScore W2898093807C2776364478 @default.
• W2898093807 hasConceptScore W2898093807C2776694085 @default.
• W2898093807 hasConceptScore W2898093807C2776755627 @default.
• W2898093807 hasConceptScore W2898093807C2777292972 @default.
• W2898093807 hasConceptScore W2898093807C2777478702 @default.
• W2898093807 hasConceptScore W2898093807C2779289229 @default.
• W2898093807 hasConceptScore W2898093807C2779429289 @default.
• W2898093807 hasConceptScore W2898093807C2779901536 @default.
• W2898093807 hasConceptScore W2898093807C502942594 @default.
• W2898093807 hasConceptScore W2898093807C555293320 @default.
• W2898093807 hasConceptScore W2898093807C71924100 @default.
• W2898093807 hasConceptScore W2898093807C98274493 @default.
• W2898093807 hasIssue "10" @default.
• W2898093807 hasLocation W28980938071 @default.
• W2898093807 hasLocation W28980938072 @default.
• W2898093807 hasOpenAccess W2898093807 @default.
• W2898093807 hasPrimaryLocation W28980938071 @default.
• W2898093807 hasRelatedWork W1713016576 @default.
• W2898093807 hasRelatedWork W1985097667 @default.
• W2898093807 hasRelatedWork W1997231640 @default.
• W2898093807 hasRelatedWork W2038870052 @default.

• next